Pillstats
Rx only · Capsule · Oral

Lisdexamfetamine

Lisdexamfetamine Dimesylate

3 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US19 NDCs
3 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCN06BA12
RxCUI (US)700810
US makers3 labelers
Packages19
DEA / ScheduleCII

US acquisition costNADAC · per unit

Average across 13 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$0.927$1.85$2.78$3.71Dec 2025Apr 2026Jul 2026
$2.780
Latest avg · Jul 22, 2026
-14%
Since Dec 17, 2025
3
Active US suppliers
68%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

31K61K92K122K2025 Q12025 Q22025 Q32025 Q42026 Q1
106K
Rx · 2026 Q1
3.1M
Units dispensed
+47%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it3 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Mylan Pharmaceuticals Inc.unknown7SUPPLYING
AvKAREunknown6SUPPLYING
Amneal Pharmaceuticals LLCunknown6SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Jul 14, 2023
    SHORTAGEDrug shortage: Lisdexamfetamine Dimesylate Capsule (Mylan Pharmaceuticals Inc., a Viatris Company)

    Lisdexamfetamine Dimesylate Capsule — reported in shortage by Mylan Pharmaceuticals Inc., a Viatris Company. Therapeutic category: Psychiatry.

  • Jul 14, 2023
    SHORTAGEDrug shortage: Lisdexamfetamine Dimesylate Capsule (Amneal Pharmaceuticals)

    Lisdexamfetamine Dimesylate Capsule — reported in shortage by Amneal Pharmaceuticals. Therapeutic category: Psychiatry.